News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ADMA Biologics, Inc. Announces Closing of Initial Public Offering


10/23/2013 11:58:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RAMSEY, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the closing of its previously announced initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share. Aggregate net proceeds to ADMA, after deducting underwriting discounts and commissions will be approximately $26.5 million.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES